The purpose of this study is to compare the usual approach of observation (closely watching a patient’s condition after surgery) to taking an immunotherapy drug, durvalumab (MEDI4736).
Learn more about the S2414/INSIGHT trial or call the Cancer Research Office at Reading Hospital 484-628-8193.
